Department of Ophthalmology and Visual Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Department of Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Int Ophthalmol. 2023 Sep;43(9):3391-3401. doi: 10.1007/s10792-023-02747-6. Epub 2023 May 17.
The purpose of the study was to report three cases of orbital inflammation following administration of the COVID-19 vaccination, manifesting as Tolosa-Hunt syndrome (THS) and orbital myositis.
A retrospective case series and literature review of patients who developed orbital inflammation following a COVID-19 vaccination.
One patient presented with Tolosa-Hunt syndrome (THS) 14 days following her third (booster) COVID-19 vaccination, one patient developed orbital myositis 10 days following his first COVID-19 vaccination and one patient developed recurrent orbital myositis 1 and 7 days following her second and fourth COVID-19 vaccination. All patients received the Comirnaty vaccine (Pfizer-BioNTech). A thorough systemic autoimmune disease workup in both patients was unremarkable. Two patients had a prior history of orbital inflammation, with previous involvement of other different orbital structures. Characteristic MRI features for each pathology were observed, supporting the clinical presentation of THS and orbital myositis. There was complete resolution of THS following corticosteroids, with no recurrence at 2 months. Meanwhile, one case of orbital myositis self-resolved at 2 months without use of systemic corticosteroids, while the other patient with orbital myositis required treatment with intra-orbital steroid injections and oral corticosteroids.
Orbital inflammation has been recognised as a rare adverse effect following COVID-19 vaccination. We present a case series of THS and orbital myositis as varied presentations of this entity.
本研究旨在报告 3 例 COVID-19 疫苗接种后发生的眶内炎症病例,表现为托洛萨-亨特综合征(THS)和眶肌炎。
回顾性病例系列研究和 COVID-19 疫苗接种后发生眶内炎症的患者文献复习。
1 例患者在第三次(加强针)COVID-19 疫苗接种后 14 天出现托洛萨-亨特综合征(THS),1 例患者在第一次 COVID-19 疫苗接种后 10 天出现眶肌炎,1 例患者在第二次和第四次 COVID-19 疫苗接种后 1 天和 7 天分别出现复发性眶肌炎。所有患者均接种了 Comirnaty 疫苗(辉瑞-生物技术)。对两名患者进行了全面的系统性自身免疫性疾病检查,均无异常。两名患者均有眶内炎症的既往史,之前累及其他不同的眶内结构。观察到每种病理的特征性 MRI 特征,支持 THS 和眶肌炎的临床表现。皮质类固醇治疗后,THS 完全缓解,2 个月无复发。同时,1 例眶肌炎在 2 个月内自行缓解,无需全身皮质类固醇治疗,而另 1 例眶肌炎患者需要眶内类固醇注射和口服皮质类固醇治疗。
眶内炎症已被认为是 COVID-19 疫苗接种后的罕见不良反应。我们提出了一系列 THS 和眶肌炎病例,这些病例表现各异。